Building the Foundation for Modern Medicine: Our Series B Investment in Forus

Every year, hundreds of billions of dollars are spent developing new therapies: miracles of modern science that can cure disease and save lives. Yet as scientific progress has accelerated, the system to deliver these therapies into the hands of patients has not kept up. Patients and providers alike must navigate an endless stream of forms, faxes, and phone calls, which can drag on for weeks or even months. In an era of breakthrough drugs, a patient can have the right doctor, the right diagnosis, and the right medicine, and still not get treated.

Forus was founded to fix this. Its AI platform automates every step between prescription and fulfillment, replacing the manual workflows of the past with an end-to-end solution that is built for modern medicine. Providers can send prescriptions to Forus and the platform automatically finds the best path to approval, saving hours of administrative work each week. Patients can finally access medications quickly and affordably, with full visibility throughout the entire process. It's a magical experience that has propelled the Forus network to 10x annual provider growth for two consecutive years -- driven entirely by word of mouth.

Forus replicates many of the patterns from the successful "AI 1.0" companies of the past couple years, leveraging state-of-the-art models to automate structured work and ride the frontier of model capabilities. Amplifying this is the compounding value of the platform over time. Every combination of drug, indication, and payer has historically required a different path to approval, with constantly changing rules that no single stakeholder has encoded. By owning the entire prescription flow end-to-end, Forus has a flywheel that compounds to its users' benefit: the more prescriptions Forus processes, the better the product gets, and the more patients get treated.

What makes Forus unique is they have been architected from the ground up for a world where intelligence is commoditized and pricing rounds to zero; the product is completely free for patients and providers. In that sense, we believe they represent one of the first "AI 2.0" companies, focused on building the largest network possible to create the most value possible for the ecosystem, including and especially our life sciences partners. As AI accelerates drug discovery, Forus has a unique view of where providers get stuck, where patients drop off, and how medicines perform across populations. These insights help life sciences companies better invest in hard-to-treat conditions and bring new therapeutics to market more efficiently. Already, 5 of the top 10 pharmaceutical companies work with Forus, and we believe this will continue to grow.

The company was founded by Sahir Jaggi, who we initially got to know as a product leader at Oscar Health. Sahir's experience at Oscar gave him a clear perspective on both the complexities of the healthcare ecosystem and the network approach that would actually align incentives and create value. From the moment we met Sahir, we were impressed by his vision and drive -- but the need for Forus was most evident in the feedback from early users. Patients told us they could access life-changing medication for the first time, while physicians described a newfound confidence to prescribe effective treatments that would actually reach their patients. Building alongside Sahir is an equally impressive team of entrepreneurial engineers, AI researchers, and healthcare veterans.

We are proud to announce that Accel is leading Forus's Series B financing, alongside our friends at Thrive and General Catalyst. Sahir and the Forus team have more to say about the round here. Forus joins a growing set of category-defining AI companies in the Accel family, and we are excited to partner with them as they build the foundation for modern medicine.